Assetmark, Inc Cytokinetics Inc Transaction History
Assetmark, Inc
- $45.6 Billion
- Q3 2025
A detailed history of Assetmark, Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Assetmark, Inc holds 3,363 shares of CYTK stock, worth $202,788. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,363
Previous 2,642
27.29%
Holding current value
$202,788
Previous $87,000
111.49%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CYTK
# of Institutions
390Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.06 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$885 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$715 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$472 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$384 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.68B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...